Lipid and pleiotropic effects of atorvastatin in patients with acute coronary syndrome

Aim. To study the effects of an HMG-CoA reductase inhibitor atorvastatin in patients with acute coronary syndrome (ACS).

Material and methods. The study included 116 ACS patients, divided into two comparable groups. Total follow-up time was 180±7 days.

Results. In 6 months of the follow-up, the patients receiving atorvastatin demonstrated better clinical effectiveness, left ventricular hypertrophy regression, ejection fraction increase by 16,5% (р<0,05), improved microcirculation and endothelial function. Atorvastatin was also linked to reduced incidence and duration of ischemic episodes and lower incidence of cardiac arrhythmias. Only the patients receiving atorvastatin achieved target levels of blood lipids and demonstrated significant improvement in blood rheology and coagulation. In the atorvastatin group, the levels of von Willebrand factor and C-reactive protein were by 28,8% (р<0,01) and 60,2% (p<0,001) lower than those in the control group, respectively.

Conclusion. Atorvastatin improved endothelial function, myocardial perfusion, and central and peripheral hemodynamics in ACS patients, which facilitated a less severe clinical course of the disease.

1. Арутюнов Г.П. Статины и острые коронарные синдромы. Мы на пороге нового стандарта лечения. Клин фармакол и терапия 2001; 3(10): 2-8.

2. Балуда В.П., Балуда М.В., Деянов И.И., Тлепшуков И.К. Физиология системы гемостаза. Москва 1995.

3. Баринов В.Г. Плазменные, тромбоцитарные и эндотелиальные факторы в диагностике нарушений гемостаза и реологии крови у больных различными формами ИБС. Автореф дисс докт мед наук. Москва 2001.

4. Викентьев В.В. Ишемия миокарда и нарушение диастолической функции левого желудочка. РМЖ 2000; 8(5): 21821.

5. Грацианский Н.А. Нестабильная стенокардия – острый коронарный синдром. Некоторые новые факты о патогенезе и их значении при лечении. Кардиология 1996; 11: 4-16.

6. Маянская С.Д., Куимов А.Д. Эндотелиальная дисфункция и острый коронарный синдром. РКЖ 2001; 2(28): 76-84.

7. Панченко Е.П. Механизмы развития острого коронарного синдрома. РМЖ 2000; 8(109): 359-64.

8. Шевченко О.П., Шевченко А.О. Статины ингибиторы ГМГ-КоА-редуктазы. Москва: Реафарм 2003.

9. Явелов И.С. Современные подходы к раннему лечению острого инфаркта миокарда. РМЖ 1998; 6(2): 72-82.

10. Aviram M, Hussein O, Rosenblat M, et al. Interactions of platelets, macrophages, and lipoproteins in hypercholesterolemia: antiatherogenic effects of HMG-CoA reductase inhibitor therapy. J Cardivasc Pharmacol 1998; 31: 39-45.

11. Carlson CS, Aldred SF, Lee PK, et al. Polymorphisms within the C-reactive protein (CRP) promoter region are associated with plasma CRP levels. Am J Hum Gene 2005; 77: 64-77.

12. Feron O, Dessy C, Desager JP, et al. Hydroxymethylglutarylconezyme A reductase inhibition promotes endothelial nitric oxide synthase activation through a decrease in caveolin abundance. Circulation 2001; 103: 113-8.

13. Ferro D, Basili S, Alessandri С, et al. Inhibition of tissuefactormediated thrombin generation by simvastatin. Atherosclerosis 2000; 149: 111-6.

14. Hayes OW. Emergency management of acute myocardial infarction. Focus on pharmacological therapy. Am Med Clin North Am 1998; 16(3): 541-63.

15. Laufs U, Fata VL, Liao JK. Inhibition of 3-hydroxy-3methylglutaryl (HMG)-CoA reductase blocks hypoxiamediated down-regulation of endothelial nitric oxide synthase. J Biol Chem 1997; 272: 31725-9.

16. Pasceri V, Chang J, Willerson JT, et al. Modulation of C-reactive protein-mediated monocyte chemoattractant protein-1 induction in human endothelial cells by antiatherosclerotic drugs. Circulation 2001; 103: 2531-4.

17. Ridker PM, Cannon CP, Morrow D, et al. C-reactive protein levels and outcomes after statin therapy. N Eng J Med 2005; 352: 20-8.

18. Rosenson RS, Tangney CC, Schaefer EJ. Comparative study of HMG-CoA reductase inhibitors on fibrinogen. Atherosclerosis 2001; 155: 463-6.

19. Ross A, Molhoek P, Lundergan C, et al. Randomized Comparison of Enoxaparin Low–Molecular–Weight Heparin With Unfractionated Hepаrin Adjunctive to Recombinant Tissue Plasminogen Activator Thrombolysis and Aspirin Second Trial of Hepаrin and Aspirin Reperfusion Therapy (HART II). Circulation 2001; 104: 648-52.

20. Weber C, Erl W, Weber K. HMG-CoA reductase inhibitors decrease CD11b expression and CD11b-dependent adhesion of monocytes to endothelium and reduce increased adhesiveness of monocytes isolated from patient with hypercholesterolemia. JACC 1997; 30: 1212-7.